Momenta Pharmaceuticals (MNTA)
Momenta Pharmaceuticals Revenues: 24.23M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MNTA Revenues Rankings
| Overall | 24th percentile | 3347 of 4432 |
| Sector | 49th percentile | 240 of 471 in Healthcare |
| Industry | 69th percentile | 40 of 132 in Biotechnology |
MNTA Revenues Range, Past 5 Years
| Minimum | 2.795M | Jun 2010 |
| Maximum | 87.94M | Sep 2011 |
| Average | 23.91M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these MNTA related companies
MNTA News
Momenta to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
May 30, 8:30AM GlobeNewswire
May 30, 8:30AM GlobeNewswire
Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Copaxone Preview
May 29, 8:24AM Street Insider
May 29, 8:24AM Street Insider
Momenta to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 11, 8:00AM GlobeNewswire
May 11, 8:00AM GlobeNewswire
Momenta Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
May 03, 3:50PM Seeking Alpha
May 03, 3:50PM Seeking Alpha
Listen to $MNTA Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3eFT
about 28 days ago by earningscast
about 28 days ago by earningscast
Momenta Pharmaceuticals Announces Date of First Quarter 2012 Financial Results Conference Call
Apr 20, 8:30AM GlobeNewswire
Apr 20, 8:30AM GlobeNewswire
Option Alert: Momenta Pharmaceuticals May 19 Call; Block Trade, 4,577 Contracts
Apr 18, 3:35PM Benzinga
Apr 18, 3:35PM Benzinga
Momenta Pharmaceuticals CEO Presents at 2012 Citi Global Health Care Conference (Transcript)
Mar 14, 4:32AM Seeking Alpha
Mar 14, 4:32AM Seeking Alpha
Momenta to Present at the Barclays Capital Global Healthcare Conference
Mar 12, 12:30PM GlobeNewswire
Mar 12, 12:30PM GlobeNewswire
Momenta Pharmaceuticals and Sunpeaks Ventures Making Headway in Lucrative Anticoagulant Market
Mar 12, 8:20AM Marketwire
Mar 12, 8:20AM Marketwire
Momenta to Present at the Cowen and Company 32nd Annual Health Care Conference
Mar 02, 3:30PM GlobeNewswire
Mar 02, 3:30PM GlobeNewswire
Momenta to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb 13, 5:00PM GlobeNewswire
Feb 13, 5:00PM GlobeNewswire
Momenta Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 09, 4:21PM Seeking Alpha
Feb 09, 4:21PM Seeking Alpha
Listen to $MNTA Q4 2011 earnings call (EPS -0.02 vs est 0.27) - live at 10:00 AM, ondemand after - http://stks.co/2KHY
about 112 days ago by earningscast
about 112 days ago by earningscast
$MNTA Reports Q4 EPS $(0.02) vs $0.27 Est; Revenues $26.10M vs $38.59M Est
about 112 days ago by Benzinga
about 112 days ago by Benzinga
Momenta Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year End 2011
Feb 09, 8:30AM GlobeNewswire
Feb 09, 8:30AM GlobeNewswire
Most leaders survived today. Some casualties $GNC $MNTA. Watch your stocks & watch your stops. Watch the dip & see if they buy it $SPY $QQQ
about 125 days ago by TradetheLeaders
about 125 days ago by TradetheLeaders
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MNTA | 13.83 | -0.14 | -1.00% | 709.89M |
| MNST | 73.64 | +0.60 | +0.82% | 12.84B |
| MNRO | 34.12 | -0.34 | -0.99% | 1.053B |
| MNRK | 9.95 | +0.00 | +0.00% | 59.10M |
| MNR | 10.22 | +0.04 | +0.39% | 410.54M |
| MNOV | 1.73 | -0.01 | -0.75% | 27.84M |
| MNKD | 1.83 | -0.01 | -0.54% | 306.47M |
| MNI | 2.19 | -0.02 | -0.91% | 187.05M |
| MNE | 15.25 | +0.14 | +0.89% | |
| MNDO | 1.70 | -0.01 | -0.58% | 31.84M |
